NEUREN PHARMACEUTICALS LIMITED
ASX:NEUPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 97.9% of what they think they own, once every option and right converts.
2% of shares in the money
NEUREN PHARMACEUTICALS LIMITED's ordinary share count declined 0.8% between June 2024 and June 2026, standing at 127M shares. The company did not raise capital in the past 24 months and has no proposed securities issues pending. Options and rights on issue could convert into 3M new shares, representing 2.2% of the current share count, of which 2% are in the money; the nearest expiry is February 2029. NEUREN PHARMACEUTICALS LIMITED no longer lodges quarterly cash reports, so no cash balance or funding runway figure is disclosed on that basis.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 18 June 2026 | 2A · quoted issue | NEU : ORDINARY FULLY PAID | 126.8M | Appendix 2A |
| 1 June 2026 | 3G · unquoted | NEU : ORDINARY FULLY PAID | 126.4M | Appendix 3G |
| 1 June 2026 | 3H · cancellation | NEU : ORDINARY FULLY PAID | 126.3M | Appendix 3H |
| 11 May 2026 | 3H · cancellation | NEU : ORDINARY FULLY PAID | 126.4M | Appendix 3H |
| 10 Apr 2026 | 3H · cancellation | NEU : ORDINARY FULLY PAID | 126.5M | Appendix 3H |
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
At $20.21 today, 2.5M securities are in the money (2.0% of shares on issue). No more priced supply until 1.25× today’s price, which takes it to 2.7M (2.2% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| NEUAAC | Options | Price-triggered | $23.09 | 7 Feb 2029 | 260k | Filing |
| NEUAA | Options | Price-triggered | $12.91 | 23 May 2030 | 1.8M | Filing |
| NEUAB | Options | Price-triggered | $14.10 | 9 July 2030 | 210k | Filing |
| NEUAAD | Options | Price-triggered | $19.63 | 19 Sept 2030 | 115k | Filing |
| NEUAD | Options | Price-triggered | $13.62 | 27 May 2031 | 360k | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 5 Mar 2026 | Joseph Basile | Buy on-market | 12k | — | — | $152k | 3Y notice |
| 8 Sept 2025 | Jonathan Pilcher | Sell on-market | — | — | — | — | 3Y notice |
| 22 July 2025 | Jonathan Pilcher | Buy | 1.5M | — | — | $2.8M | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.